RobertLRednerMD

Hematology • Pittsburgh, PA

Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Redner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Redner's full profile

Already have an account?

Office
5115 Centre Avenue
Upmc Cancer Pavillion
Pittsburgh, PA 15232
Phone+1 412-692-4724

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
Harvard Medical SchoolClass of 1980

Certifications & Licensure

CA State Medical License 1983 - Present
PA State Medical License 1991 - 2024
MD State Medical License 1984 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
Terminated
Phase 1
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Jan 01
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome Start of enrollment: 2011 Apr 01
Completed
Phase 1
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma Start of enrollment: 2008 Feb 01
Completed
Phase 1
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

429 citations
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Jianxiang Wang, Taizo Hoshino, Robert L. Redner, Sachiko Kajigaya, Johnson M. Liu
Proceedings of the National Academy of Sciences of the United States of America. 1998-09-01
602 citations
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter, James B. Bussel, Roger M. Lyons, Vinod Pullarkat, Terry Gernsheimer
Lancet. 2008-02-02
120 citations
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Michael Boyiadzis, Mounzer Agha, Robert L. Redner, Alison R. Sehgal, Annie Im
Cytotherapy. 2017-10-01

Grant Support

Characterization Of A Novel Translocation Product In APLNational Cancer Institute2006–2009
Calcitriol &Dexamethasone For Myelodysplastic SyndromesFood And Drug Administration2004
Vitamin D And Dexamethasone In Myelodysplastic SyndromesNational Cancer Institute2002–2003
Novel Translocation Product In APLNational Cancer Institute1995–1999